Week Ending September 13, 2021

Biomarker testing decisions for lung cancer vary between academic, community oncologists
“Considerably fewer community oncology clinicians than academic clinicians use biomarker testing to guide discussions with patients with lung cancer, according to survey results.”

Atezolizumab Combo Demonstrates Favorable Efficacy and Safety Data for NSCLC with Untreated Brain Metastases
“Patients with non-small cell lung cancer with brain metastases experienced a favorable safety profile along with efficacy results when treated with atezolizumab plus chemotherapy.”

Patients With ALK+ NSCLC Not Suitable for Crizotinib Benefit from Sequential ALK-Inhibitor Therapy
“Patients with non–small cell lung cancer harboring ALK mutations who were not suitable for crizotinib therapy, either due to resistance or intolerance, showed benefit with sequential crizotinib and alectinib.”

NIH study illuminates origins of lung cancer in never smokers
“A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body. This study was conducted by an international team led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and describes for the first time three molecular subtypes of lung cancer in people who have never smoked.”

Improvements in Radiation Therapy May Confer Better Treatment for Lung Cancer
“Increased use of radiation in lung cancer treatment may be a result of discoveries in research and improved spreading of information on this technology.”

AI can spot signs of lung cancer on CT scans a year earlier
“An artificial intelligence (AI) program can spot signs of lung cancer on CT scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.”

VIDEO:
Dr. Osarogiagbon on Geographic Disparities in Lung Cancer Mortality Rates in the United States
“Raymond U. Osarogiagbon, MD, medical oncologist, Baptist Cancer Center, discusses geographic disparities in lung cancer mortality rates across the United States.”

Alexander Spira, MD, PhD, FACP, Discusses Biomarker-Guided Treatment in Lung Cancer at 2021 WCLC
“At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about the approval of drugs for mutations such as KRAS G12C and how there are more in development to target these aberrations.”